Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICAM1 | P05362 | 1/20 | 0.37 |
| ▸ | SELE | P16581 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14952680 | 1.00 | ICAM1 (0.37) | ICAM1SELECREBBPCNR1CNR2 | |
| SCHEMBL14952710 | 0.96 | ICAM1 (0.38) | ICAM1SELECREBBPCNR1CNR2 | |
| SCHEMBL9891694 | 0.94 | ICAM1 (0.39) | ICAM1SELECREBBPTACR1MEN1 | |
| SCHEMBL15373278 | 0.93 | NAAA (0.40) | ICAM1SELECREBBPCNR1CNR2 | |
| SCHEMBL14952712 | 0.93 | ICAM1 (0.37) | ICAM1SELECREBBPCNR1CNR2 | |
| SCHEMBL14952867 | 0.90 | ICAM1 (0.43) | ICAM1SELECREBBPCNR1CNR2 | |
| SCHEMBL15831445 | 0.90 | ICAM1 (0.38) | ICAM1SELECREBBPMEN1KMT2A | |
| SCHEMBL14650422 | 0.90 | ICAM1 (0.38) | ICAM1SELECREBBPMEN1KMT2A | |
| SCHEMBL14650387 | 0.89 | ICAM1 (0.41) | ICAM1SELECREBBPTACR1MEN1 | |
| SCHEMBL15373364 | 0.89 | ICAM1 (0.37) | ICAM1SELECREBBPCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912348-B2 | Tetrahydropyranyl compound and method for producing the tetrahydropyranyl compound | RICOH COMPANY, LTD. (JP) | 2014-12-16 | — | — | US | disclosed |
| US-20120142948-A1 | TETRAHYDROPYRANYL COMPOUND AND METHOD FOR PRODUCING THE TETRAHYDROPYRANYL COMPOUND | RICOH COMPANY, LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142948-A1 | TETRAHYDROPYRANYL COMPOUND AND METHOD FOR PRODUCING THE TETRAHYDROPYRANYL COMPOUND | CYP4A11, CYP11B1, CYP11B2 | ICAM1 4603/4885SELE 4853/4885CREBBP 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.